cenerimod

Small moleculeexperimental

Clinical trial activity

14 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
7
Phase 2
7
Phase 3
4
Phase 4
0

Earliest trial started May 1, 2015 (NCT02479204)

Timeline

2010s

  1. Jan 1, 2015

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2015

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CCc1cc(-c2noc(-c3cc(OC)nc(C4CCCC4)c3)n2)cc(C)c1OC[C@@H](O)CO
Mol. weight
453.54 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • act-334441
  • act-334441
  • cenerimod
  • cenerimod
  • cenerimod

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07301723Phase 1Dec 31, 2025Viatris
NCT07201129Phase 3Dec 31, 2025Viatris
NCT07266090Phase 2Nov 28, 2025Mylan
NCT06475742Phase 3Jul 30, 2024Idorsia Pharmaceuticals Ltd.
NCT05672576Phase 3Jun 26, 2023Idorsia Pharmaceuticals Ltd.
NCT05648500Phase 3Dec 13, 2022Idorsia Pharmaceuticals Ltd.
NCT05004311Phase 1Sep 27, 2021Idorsia Pharmaceuticals Ltd.
NCT04819464Phase 1Aug 19, 2021Idorsia Pharmaceuticals Ltd.
NCT04255277Phase 1Feb 29, 2020Idorsia Pharmaceuticals Ltd.
NCT04052360Phase 1Aug 29, 2019Idorsia Pharmaceuticals Ltd.
NCT03742037Phase 2Dec 21, 2018Idorsia Pharmaceuticals Ltd.
NCT02914223Phase 1Sep 1, 2016Actelion
NCT02472795Phase 2Jun 1, 2015Actelion
NCT02479204Phase 1May 1, 2015Actelion
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Idorsia Pharmaceuticals Ltd.For profit8832018
ActelionFor profit3322015
ViatrisFor profit2222025
MylanFor profit1112025
4 organizations
Page 1 / 1